Stereochemistry | ACHIRAL |
Molecular Formula | C17H16N2S |
Molecular Weight | 280.387 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C(CC1=CC=CC=C1)NC2=NC(=CS2)C3=CC=CC=C3
InChI
InChIKey=WEEYMMXMBFJUAI-UHFFFAOYSA-N
InChI=1S/C17H16N2S/c1-3-7-14(8-4-1)11-12-18-17-19-16(13-20-17)15-9-5-2-6-10-15/h1-10,13H,11-12H2,(H,18,19)
Molecular Formula | C17H16N2S |
Molecular Weight | 280.387 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Fanetizole is a derivative of 2-aminothiazole. It is an anti-inflammatory agent. This drug is reported to have some cyclooxygenase inhibiting activity. Production of superoxide in response to the chemotactic factor formyl-methionyl-leucyl-phenylalanine (f-Met-Leu-Phe) was markedly inhibited by fanetizole. Suppression of neutrophil production of toxic oxygen metabolites may partially explain the antiarthritic effect of fanetizole. Fanetizole was shown to restore depressed E-rosetting activity in adult thymectomized mice, as well as enhance in in vitro proliferation of murine thymic cells to mitogen and synergistically acted with the monokine interleukin-1. It displays anti-arthritic activity in viva in the rat adjuvant arthritis model, inhibiting the development of disease in the non-infected foot. This drug has less side effects than levamisole in animals.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
B cells from 16 atopic subjects without eczema produced de novo a mean of 516 pg/ml of IgE without the drug and 196 pg/ml in the presence of 2.5 x 10(-4) M drug. B cells from 6 atopic subjects with eczema synthesized a mean of 1984 pg/ml of IgE in the absence of the drug and 1486 pg/ml in the presence of 2.5 x 10(-4) M drug.